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life, with an increase in costs of about €540–640 and €680–
780/patient/year with solifenacin and tolterodine, respectively.
Cost-utility analysis indicates that solifenacin dominates toltero-
dine and has an ICUR in the range €7,600—18,600/QALY com-
pared to no treatment. In the subgroup of patients incontinent
at baseline and who respond to the therapy, the increase in costs
with solifenacin results in €100–400/patient/year. The expected
incremental expenditure of the theoretical reimbursement deci-
sion is about €23 millions/year, with an ICUR of about €600–
2,400/QALY. CONCLUSIONS: Solifenacin has the potential to
improve current clinical outcomes of many Italian OAB
patients, at a mean net cost of €540–640/year. The ICUR of the
hypothesized reimbursement decision can expected to be very
favourable.
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OBJECTIVES: Recent clinical data show that a supplemented
very low protein diet (sVLPD) allows to postpone dialysis (HD/
PD) of about one year without increasing risk of death or hospi-
talization in CKD5 elderly patients; here we compared beneﬁts
and costs of sVLPD vs dialysis in these patients. METHODS: A
cost-beneﬁt analysis technique was applied. Direct medical and
non-medical beneﬁts and costs were analysed, from the perspec-
tive of the Italian National Health Service (NHS). We quantiﬁed
resource adsorption for dialysis, keto-amino acid supplements,
hospitalizations, pharmacological therapy, blood and instrumen-
tal tests, medical visits, reimbursement for transportation of
patients in HD and for home treatment of patients in PD. Prices
and tariffs applied in 2007 were used. Results are expressed as
mean € per patient-year. RESULTS: Data from a subgroup of
patients with GFR of 5–7 ml/min/1.73 m2 BSA, participating in a
RCT were analysed. Thirty patients were randomized to dialysis
(age = 77.2 4.6 years; 23 HD, 7 PD); 27 to sVLPD (age = 78.6 6.5
years): during the follow up 19 switched to HD and 2 to PD.
Follow-up was, in mean, 3.24 years in dialysis, and 3.27 years in
sVLPD group, including both diet and following period on dialy-
sis. Erythropoietin (EPO) dose was on average 7,160 IU/patient-
week in sVLPD patients, and 8,104 IU/patient-week in dialysis
patients. Patients cost €45,209/patient-year on dialysis; €10,786/
patient-year during sVLPD and €40,900/patient-year when
shifted to dialysis. Dialysis was the cost driver (€26,000/patient-
year, 60% of costs), main beneﬁt to NHS derived from saving
this costs in the ﬁrst year (mean period in sVLPD) of treatment.
CONCLUSIONS: to our knowledge this is the ﬁrst study analys-
ing beneﬁts and costs of initiating sVLPD whereas dialysis in
CKD5 patients. sVLPD allows to save 1 year per patient of dialysis
and to gain €34,000/patient-year on the NHS’s perspective.
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OBJECTIVES: Overactive bladder is a dysfunction of the lower
urinary tract which causes signiﬁcant impairment to patients’
quality of life and affects a relatively large portion of the popu-
lation. Patients who have failed all conservative treatment
options are faced with managing their incontinence symptoms
through the daily use of incontinence pads, or their retention by
frequent clean intermittent self catheterization. Patients with
severe symptoms may be offered a highly invasive surgical pro-
cedure, such as myectomy, urinary diversion or bladder augmen-
tation but these are all associated with serious complications and
morbidity. The objective is to assess cost-effectiveness of sacral
neuromodulation as a second line treatment option for patients
with OAB in the Dutch setting. METHODS: An economic model
comparing sacral neuromodulation with optimal medical treat-
ment was developed. Health states were deﬁned in terms of ‘cure’
deﬁned as no incontinence or a clinical improvement > 90%,
or ‘improvement’ deﬁned as 50% or greater reduction in main
continence or urgency frequency symptoms. Associated clinical
effectiveness and utility values were taken from published inter-
national clinical studies, and treatment costs were based on
national sources. Analyses from the health care payer’s perspec-
tive were performed for a 10 year time-horizon. RESULTS: The
results of the deterministic cost-effectiveness analysis showed
that sacral neuromodulation provides an additional 1.53 QALY’s
against extra cost of €8222 per patient over a 10 year period.
The corresponding cost-effectiveness ratio was €5732 per QALY
gained. Probabilistic sensitivity analysis showed the robustness of
these results. CONCLUSIONS: Use of sacral neuromodulation
as a treatment option for patients with OAB in The Netherlands
will improve patients’ outcomes at a reasonable cost.
PUK7
ATEN-YEAR HORIZON COST-EFFECTIVENESS ANALYSIS
OFTHE SPANISH INTEGRATED RENAL REPLACEMENT
THERAPY PROGRAM
Villa G1, Cuervo J1, Ortiz LF1, Sánchez JE2, Rebollo P1
1BAP Health Outcomes Research, Oviedo, Asturias, Spain, 2Hospital
Universitario Central de Asturias, Oviedo, Asturias, Spain
OBJECTIVES: Performing a 10-year horizon (2007/2016) cost-
effectiveness analysis of the integrated Spanish Renal Replace-
ment Therapy (RRT) program, from the National Health System
perspective. METHODS: A deterministic Markov chain model,
allowing for incident patients, was designed to predict transitions
between four states (hemodialysis (HD), peritoneal dialysis (PD),
renal transplant (TX), and death (D)) for the period 2007/2016,
providing future incidence, prevalence, and survivability esti-
mates. Transition and mortality probabilities were calibrated
using data from the Spanish Nephrology Society (SEN) and the
Spanish National Statistics Institute (INE) for the period 1996/
2006. Information on direct and indirect costs was gathered from
several sources, including OBLIKUE database, regional ofﬁcial
bulletins, literature review, and expert judgment. Data on utilities
were obtained from a proprietary database (FIS 96/1327
Project). A sensitivity analysis on the main parameters of the
model was performed in order to ensure that results were con-
sistent. RESULTS: For the 2007/2016 period, average patients
per year (HD, PD, and TX) were, respectively: 29,981; 3,348;
26,301. Average costs per patient and year (in 2007 discounted
Euros) were: 39,026; 26,971; and 13,085. Average QALYs per
patient and year were: 0.51; 0.55; and 0.68. Therefore, average
cost-effectiveness was: 75,927; 49,478; and 19,253. TX was the
optimal treatment, regarding cost-effectiveness estimates. Conse-
quently, it was considered as the gold standard. Incremental
Cost-Effectiveness Ratios were: -103,233 (TX vs. HD) and
-156,636 (TX vs. PD). Net Health Proﬁts were: 1.03 (TX vs.
HD) and 0.60 (TX vs. PD). Consistency of these ﬁndings was
supported by the sensitivity analysis. CONCLUSIONS: As
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expected, TX is the most convenient treatment, as regards cost-
effectiveness estimates. PD is also preferred to HD. National
Health System authorities should, therefore, favor PD over HD.
If that is the case, a Budget Impact Analysis would help to assess
to which extent such approach would be worthy.
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OBJECTIVES: Health economic analyses are used routinely to
evaluate a number of types of health care interventions and are
required for all new pharmaceuticals by many national and
regional health authorities. These analyses assess the implications
of projected outcomes and costs of a new drug treatment and are
often used as a tool to guide decisions about pharmaceutical
development and consumption. As an illustrative example, an
overview of the components and construction of an economic
model is presented here using the costs and outcomes associated
with fesoterodine (FESO), a new antimuscarinic that has been
shown to be safe, tolerable, and effective for the management of
overactive bladder (OAB) in adults. METHODS: Economic
evaluations comparatively assess the costs in terms of resources
consumed and consequences of drug (eg, FESO therapy). The
type of analysis illustrated is a cost utility analysis (CUA), which
focuses particular attention on the costs and incremental health
improvement attributable to fesoterodine. The costs of treatment
are measured in monetary units and include medical costs pur-
chased by the health care system, including physician visits,
diagnostic and laboratory tests, hospitalizations, and so forth.
Other costs consist of the patient’s out-of-pocket expenses for
goods and services outside of the medical sector, such as incon-
tinence pads. Unpurchased resources consumed by patients with
OAB include lost productivity while at work or lost time from
work owing to the condition. Health improvement due to FESO
is measured by quality-adjusted life years (QALYs, pronounced
“qualies”). The QALY is a measure of health outcome, which
assigns to each period of time a weight, ranging from zero (death)
to one (perfect health) corresponding to the quality of life during
that period. The need for incorporating QALYs, rather than life
years or expectancy, is due to the observation that many medical
interventions, such as those for OAB, are not associated with
premature death but with changes in morbidity and quality of
life. Finally, the central outcome in a CUA is the cost utility ratio,
the difference in the costs of the 2 alternatives divided by the
difference in QALYs. This ratio is essentially the cost of an
additional QALY when using 1 intervention compared with an
alternative. RESULTS: A CUA was created examining the costs
and beneﬁts of FESO demonstrated in a 12-week, randomized,
double-blind, placebo- and active-controlled clinical trial. Com-
parators were FESO 4 mg/d, FESO 8 mg/d, extended-release
tolterodine 4 mg/d (TOL), and solifenacin (SOL). SOL was not
included in the clinical trial, therefore efﬁcacy data were obtained
from the published literature. Medical costs of OAB (antimusca-
rinic drugs, physician visits, laboratory tests, and OAB-related
comorbidities), patient out-of-pocket costs (incontinence pads),
and productivity costs (lost productivity at work and lost time
from work) were all considered. Health-related quality of life
data were collected during the trial via the King’s Health Ques-
tionnaire (KHQ). Using a published algorithm, responses to the
KHQ were transformed into QALYs. The time frame of the
analysis was extended from the 12-week trial period to 52 weeks,
and the total expected costs and the expected QALYs for each
intervention were used in 2-way comparisons. The QALYs
gained were 0.0111, 0.0115, 0.0124, and 0.0143 for TOL, SOL,
FESO 4 mg, and FESO 8 mg, respectively. The overall costs were
£1294, £1344, £1362, and £1424 for FESO 8 mg, SOL, FESO
4 mg, and TOL, respectively. CONCLUSIONS: Economic analy-
ses are used by decision makers in conjunction with clinical and
other information to decide which drug therapy provides the best
economic value. The results of our economic analysis suggest
that FESO may result in fewer overall costs and greater QALYs
gained than treatment with TOL or SOL for the management of
patients with OAB and incontinence.
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OBJECTIVES: Existing projections of the cost of overactive
bladder (OAB) in the United States (US) are incomplete and
outdated. We sought to determine the cost of OAB in the US from
a societal perspective, incorporating direct medical, direct non-
medical, and indirect costs. METHODS: We developed a
prevalence-based model with data on age- and sex-speciﬁc OAB
prevalence, health care utilization, other components of care, and
productivity. Using data from the ﬁvemost recent years of medical
literature, practice guidelines, Medicare and managed care fee
schedules, and expert panel input, we calculated the annual per
capita and total US costs. Direct costs were calculated as the
product of the age/sex-speciﬁc probability that a care component
is used, the age/sex-speciﬁc number of units used, and its unit
price. Indirect costs (lost productivity) were calculated based on
the human capital model and governmental census data. We
applied current age/sex-speciﬁc prevalence rates, treatment pat-
terns, and costs to US census population projections to project
costs of OAB in 2015 and 2020. RESULTS: Mean total annual
per capita cost in 2007 was $1991, comprised of $1500 (direct
medical), $66 (direct non-medical), and $426 (indirect). Given
that about 34 million people in the US have OAB, the total
national cost is $68.2 billion (B) ($51.4B direct medical, $2.3B
direct non-medical, and $14.6B indirect). Mean total annual per
capita costs in 2015 and 2020 would be $2010 and $2036
respectively. Given projections of ~39 million and 42 million
people with OAB in 2015 and 2020, total national costs would be
$78.8B and $85.4B, respectively. CONCLUSIONS: These data
suggest that the economic burden of OAB is about ﬁve-fold higher
than older, non-comprehensive estimates. Inasmuch as 75% of
this cost is for direct medical care, it is important that opportuni-
ties be explored to improve the value of available therapies.
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OBJECTIVES: Chronic kidney disease is a progressive condition
that results in signiﬁcant morbidity and mortality. Dietary
A652 Abstracts
